3Rs for innovating novel antibiotics: sharing resources, risks, and rewards

被引：23

作者：

So, Anthony D. ^{[1
]}

Ruiz-Esparza, Quentin ^{[1
]}

Gupta, Neha ^{[1
]}

Cars, Otto ^{[2
]}

机构：

[1] Duke Univ, Program Global Hlth & Technol Access, Sanford Sch Publ Policy, Durham, NC 27708 USA

[2] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2012年 / 344卷

关键词：

D O I：

10.1136/bmj.e1782

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：4

共 28 条

[21] Advancing Drug Innovation for Neglected Diseases-Criteria for Lead Progression
Nwaka, Solomon
Ramirez, Bernadette
Brun, Reto
Maes, Louis
Douglas, Frank
Ridley, Robert
[J]. PLOS NEGLECTED TROPICAL DISEASES, 2009, 3 (08):
[22] Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, David J.
Gwynn, Michael N.
Holmes, David J.
Pompliano, David L.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (01) : 29 - 40
[23] Why is big Pharma getting out of antibacterial drug discovery?
Projan, SJ
[J]. CURRENT OPINION IN MICROBIOLOGY, 2003, 6 (05) : 427 - 430
[24] Rai A, 2008, YALE J HLTH POLICY L, V8, P53
[25] ReAct, 2011, REACT POL SEM 23 MAY
[26] Schmid M, 2004, NATURE, V2, P239
[27] Trends in antimicrobial drug development: Implications for the future
Spellberg, B
Powers, JH
Brass, EP
Miller, LG
Edwards, JE
[J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (09) : 1279 - 1286
[28] Wellcome Trust, 2010, THER